Johnson & Johnson also reported a fourth-quarter profit ahead of expectations, buoyed by strong sales of the blood cancer therapy Darzalex.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results